Q Magis1, D Jullien2, C Gaudy-Marqueste1, K Baumstark3, M Viguier4, H Bachelez4, F Guibal4, E Delaporte5, E Karimova5, H Montaudié6, T Boye7, F Aubin8, M Beylot-Barry9, M-A Richard1. 1. Department of Dermatology, Hôpital Timone, Assistance Publique des Hôpitaux de Marseille, UMR 911, INSERM CRO2, "Centre de recherche en oncologie biologique et onco phamacologie", Aix-Marseille University, Marseille, France. 2. Department of Dermatology Hôpital Edouard Herriot, University Claude Bernard Lyon-1, University of Lyon, Lyon, France. 3. Clinical Research Platform, Assistance Publique des Hôpitaux de Marseille, EA 3279 "Qualité de vie et maladies chroniques", Aix-Marseille University, Marseille, France. 4. Department of Dermatology, AP-HP Hôpital Saint Louis, University Paris Diderot, Sorbonne Paris Cité, Paris, France. 5. Regional University Hospital, Lille, France. 6. Hôpital L'Archet, Nice, France. 7. Hôpital d'instruction des armées St Anne, Toulon, France. 8. Regional University Hospital Hôpital Jean Minjoz, Besançon, France. 9. Department of Dermatology, Hôpital Saint-André, University of Bordeaux, Bordeaux, France.
Abstract
BACKGROUND: Limited information is available regarding factors associated with long-term drug survival of infliximab for psoriasis in real life. OBJECTIVES: The main aim pf this study was to identify predictors of long-term (>12 months) drug survival among patients treated with infliximab for psoriasis in a real-world clinical setting. METHODS: Retrospectively collected data, relating to disease, patient characteristics and treatment procedures, in a multicentre observational cohort of patients with moderate-to-severe plaque psoriasis treated with infliximab at eight university hospitals, 120 of whom maintained a response to infliximab for more than 12 months, were compared with prospectively collected data in the same centres from 54 patients who experienced secondary loss of response within a 12-month period. RESULTS: Mean duration of drug survival of infliximab in patients with long-term drug survival was 41.12 months ± 20.64 SD vs. 8.5 months ± 2.43 SD in patients with a secondary loss of response. Multivariate analysis identified greater disease severity at treatment onset (PASI score >12) (OR = 5.18, 95% CI: 1.60-16.77, P = 0.006), high levels of initial psoriasis clearance (PASI-90 reduction or equivalent) (OR = 18.50, 95% CI: 4.56-74.45, P = 0.0001) and combination with methotrexate (OR = 13.15, 95% CI: 1.46-118.79, P = 0.022) as independent predictors of long-term drug survival and sustained efficacy of infliximab. CONCLUSION: Positive predictors for long-term drug survival of infliximab in real life were identified. Their impact on treatment management should be addressed in further prospective trials.
BACKGROUND: Limited information is available regarding factors associated with long-term drug survival of infliximab for psoriasis in real life. OBJECTIVES: The main aim pf this study was to identify predictors of long-term (>12 months) drug survival among patients treated with infliximab for psoriasis in a real-world clinical setting. METHODS: Retrospectively collected data, relating to disease, patient characteristics and treatment procedures, in a multicentre observational cohort of patients with moderate-to-severe plaque psoriasis treated with infliximab at eight university hospitals, 120 of whom maintained a response to infliximab for more than 12 months, were compared with prospectively collected data in the same centres from 54 patients who experienced secondary loss of response within a 12-month period. RESULTS: Mean duration of drug survival of infliximab in patients with long-term drug survival was 41.12 months ± 20.64 SD vs. 8.5 months ± 2.43 SD in patients with a secondary loss of response. Multivariate analysis identified greater disease severity at treatment onset (PASI score >12) (OR = 5.18, 95% CI: 1.60-16.77, P = 0.006), high levels of initial psoriasis clearance (PASI-90 reduction or equivalent) (OR = 18.50, 95% CI: 4.56-74.45, P = 0.0001) and combination with methotrexate (OR = 13.15, 95% CI: 1.46-118.79, P = 0.022) as independent predictors of long-term drug survival and sustained efficacy of infliximab. CONCLUSION: Positive predictors for long-term drug survival of infliximab in real life were identified. Their impact on treatment management should be addressed in further prospective trials.
Authors: Nikolai Loft; Alexander Egeberg; Mads Kirchheiner Rasmussen; Lars Erik Bryld; Christoffer V Nissen; Tomas Norman Dam; Kawa Khaled Ajgeiy; Lars Iversen; Lone Skov Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875